|
| Press Releases |
|
 |
|
| Wednesday, July 19, 2017 |
|
|
联康生物科技获香江大健康基金注资1.2亿港元 成为集团策略性股东 |
| 联康生物科技集团有限公司（「联康生物科技」、「联康」或「集团」；股份代号：690）今天宣布，集团获国内知名大型综合企业香江集团牵头的香江大健康基金注资1.2亿港元成为集团策略性股东 more info >> |
|
|
聯康生物科技獲香江大健康基金注資1.2億港元 成為集團策略性股東 |
| 聯康生物科技集團有限公司（「聯康生物科技」、「聯康」或「集團」；股份代號：690）今天宣佈，集團獲國內知名大型綜合企業香江集團牽頭的香江大健康基金注資1.2億港元成為集團策略性股東 more info >> |
|
|
HeungKong Great Health Fund I Injects HK$120 Million into Uni-Bio Science and Becomes its Strategic Shareholder |
| Uni-Bio Science Group Limited ("Uni-Bio Science", "Uni-Bio" or the "Group"; HKEx code: 690) today announced that HeungKong Great Health Fund I, led by the famed Mainland China-based corporation HeungKong Group, has invested HK$120 million in the Group and become its strategic shareholder. more info >> |
|
| Monday, February 27, 2017 |
|
|
联康生物科技旗下药物获列入国家医保药品目录 |
| 联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：690）今天宣布，其产品米格列奈今天获列入由中国人力资源和社会保障部发布的国家医保药品目录。 more info >> |
|
|
聯康生物科技旗下藥物獲列入國家醫保藥品目錄 |
| 聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：690）今天宣佈，其產品米格列奈今天獲列入由中國人力資源和社會保障部發佈的國家醫保藥品目錄。 more info >> |
|
|
Uni-Bio Science's Drugs Officially Reimbursed under the National Reimbursement Drug List |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced that its product Mitiglinide is now to be officially reimbursed under the National Reimbursement Drug List ("NRDL") published by Ministry of Human Resources and Social Security today. more info >> |
|
| Friday, August 26, 2016 |
|
|
联康生物科技集团公布二零一六年中期业绩 |
联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：690）宣布截至二零一六年六月三十日止六个月之中期业绩。集团新设立的市场准入部门有效管理招标，加上成功加强其商业平台以及成功进入新的增长省份，带动集团录得强劲的财务及营运业绩。
more info >> |
|
|
聯康生物科技集團公佈二零一六年中期業績 |
聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：690）宣佈截至二零一六年六月三十日止六個月之中期業績。集團新設立的市場准入部門有效管理招標，加上成功加強其商業平台以及成功進入新的增長省份，帶動集團錄得強勁的財務及營運業績。
more info >> |
|
|
Uni-Bio Science Group Announces 2016 Interim Results |
| Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its interim results for the six months ended 30 June 2016. more info >> |
|
| Monday, June 27, 2016 |
|
|
联康生物科技与华润紫竹就金因舒®达成战略联盟 |
| 联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：690）今天宣布，集团与华润医药集团旗下专注于在国内开发、制造及销售眼科及生殖健康用药的全资附属公司─华润紫竹药业有限公司（「华润紫竹」）签订战略联盟协议。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
万利集团与行业领袖举办首届ESG论坛 在全球减碳浪潮下开创绿色航运解决方案
Feb 5, 2026 16:24 HKT/SGT
|
|
|
卓正醫療上市在即：認購火爆 以獨特商業模式撬動業績逆勢增長
Feb 5, 2026 14:24 HKT/SGT
|
|
|
卓正医疗上市在即：认购火爆 以独特商业模式撬动业绩逆势增长
Feb 5, 2026 14:24 HKT/SGT
|
|
|
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations
Feb 5, 2026 13:00 HKT/SGT
|
|
|
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
Feb 5, 2026 12:54 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 5, 2026 12:53 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 11:55: JST
|
|
|
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners
Feb 5, 2026 11:00 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 10:55 HKT/SGT
|
|
|
雲頂新耀宣佈與麥科奧特達成MT1013獨家商業化許可協議
Feb 5, 2026 10:55 HKT/SGT
|
|
|
云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议
Feb 5, 2026 10:55 HKT/SGT
|
|
|
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 5, 2026 11:48 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 체외 진단약 등 각종 검사 키트 위탁 제조를 위한 토탈 솔루션 체계 구축
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在接受委託製造體外診斷試劑等各種檢驗套組中 確立綜合式的解決方案體制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
